New cancer drugs 'vastly overestimated', says contrarian analyst

March 31, 2015 2:32 PM

21 0

LONDON (Reuters) - A hot new class of drugs designed to help the body's own immune system fend off cancer by blocking a protein called PD-1 is going to be big - but not nearly as big as investors think, according to a new analysis.

Former top Nomura analyst Amit Roy, who now runs independent research firm Foveal, thinks sales of drugs inhibiting Programmed Death receptor (PD-1), or a related target PD-L1, will sell much less than expected.

Also read: Disney raises its bid for Fox to $71 billion

Read more

To category page